MCID: HPT004
MIFTS: 42

Hepatic Coma

Categories: Liver diseases, Neuronal diseases

Aliases & Classifications for Hepatic Coma

MalaCards integrated aliases for Hepatic Coma:

Name: Hepatic Coma 12 55 15 72
Hepatic Encephalopathy 44 72
Hepatocerebral Intoxication 12

Classifications:



External Ids:

Disease Ontology 12 DOID:12550
MeSH 44 D006501
SNOMED-CT 68 72836002
ICD10 33 K72.91
UMLS 72 C0019147 C0019151

Summaries for Hepatic Coma

MalaCards based summary : Hepatic Coma, also known as hepatic encephalopathy, is related to viral hepatitis and hepatitis a. An important gene associated with Hepatic Coma is F2 (Coagulation Factor II, Thrombin), and among its related pathways/superpathways are Sterol Regulatory Element-Binding Proteins (SREBP) signalling and FOXA2 and FOXA3 transcription factor networks. The drugs Metformin and Midazolam have been mentioned in the context of this disorder. Affiliated tissues include liver, brain and testes, and related phenotype is normal.

Related Diseases for Hepatic Coma

Diseases related to Hepatic Coma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 348)
# Related Disease Score Top Affiliating Genes
1 viral hepatitis 32.5 GPT F2 ALB
2 hepatitis a 31.1 GPT F2 ALB
3 liver cirrhosis 30.4 GPT F2 ALB
4 esophageal varix 30.4 F2 ALB
5 peritonitis 30.3 F2 ALB
6 hepatorenal syndrome 30.3 F2 ALB
7 liver disease 30.1 GPT F2 ALB
8 alcoholic liver cirrhosis 29.8 F2 ALB
9 non-a-e hepatitis 29.7 F2 ALB
10 schistosomiasis 29.7 F2 ALB
11 portal hypertension 29.7 GPT F2 ALB
12 hypersplenism 29.6 F2 ALB
13 infantile liver failure syndrome 1 29.6 GPT F2 ALB
14 autoimmune hepatitis 29.6 GPT F2
15 hepatic encephalopathy 29.6 TSPO GPT F2 ALB
16 acute liver failure 29.5 TSPO GPT F2 ALB
17 protein-energy malnutrition 29.5 GPT ALB
18 eclampsia 29.4 F2 ALB
19 cholelithiasis 29.4 GPT ALB
20 bilirubin metabolic disorder 29.4 GPT F2 ALB
21 biliary atresia 29.4 GPT ALB
22 wilson disease 29.3 GPT F2 ALB
23 hepatitis b 29.3 GPT F2 ALB
24 hepatitis e 29.2 GPT F2 ALB
25 cholangitis 29.2 GPT F2 ALB
26 alcoholic hepatitis 29.1 GPT F2 ALB
27 kwashiorkor 29.0 GPT F2 ALB
28 cholecystitis 29.0 GPT F2 ALB
29 congenital extrahepatic portosystemic shunt 11.5
30 ocular motor apraxia 11.3
31 hepatic veno-occlusive disease 11.2
32 encephalopathy 10.5
33 constipation 10.3
34 helicobacter pylori infection 10.3
35 alcohol dependence 10.3
36 portal vein thrombosis 10.3
37 intracranial hypertension 10.3
38 hepatitis 10.3
39 varicose veins 10.2
40 hepatoportal sclerosis 10.2 GPT F2
41 hepatitis d 10.2 GPT F2
42 yemenite deaf-blind hypopigmentation syndrome 10.2
43 antipyrine metabolism 10.1 F2 ALB
44 acute cystitis 10.1
45 hydrops, lactic acidosis, and sideroblastic anemia 10.1
46 kidney disease 10.1
47 epstein-barr virus hepatitis 10.1 F2 ALB
48 fournier gangrene 10.1 F2 ALB
49 abdominal tuberculosis 10.1 F2 ALB
50 budd-chiari syndrome 10.1

Graphical network of the top 20 diseases related to Hepatic Coma:



Diseases related to Hepatic Coma

Symptoms & Phenotypes for Hepatic Coma

MGI Mouse Phenotypes related to Hepatic Coma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.02 ALB DBI F2 SCN1A TSPO

Drugs & Therapeutics for Hepatic Coma

Drugs for Hepatic Coma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 321)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Midazolam Approved, Illicit Phase 4 59467-70-8 4192
3
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
4
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
5
Magnesium oxide Approved Phase 4 1309-48-4 14792
6
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
7
Clavulanate Approved, Vet_approved Phase 4 58001-44-8 5280980
8
Cefoxitin Approved Phase 4 35607-66-0 441199
9
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
10
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
11
Azithromycin Approved Phase 4 83905-01-5 447043 55185
12
Vancomycin Approved Phase 4 1404-90-6 441141 14969
13
Insulin Aspart Approved Phase 4 116094-23-6 16132418
14
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
15
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
16
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
17
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
18
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
19
Promethazine Approved, Investigational Phase 4 60-87-7 4927
20
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
21
Histamine Approved, Investigational Phase 4 51-45-6 774
22
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
23
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4 52485-79-7 40400 644073
24
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
25
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
26
Silicon Approved, Investigational Phase 4 7440-21-3 4082203
27
chloroquine Approved, Investigational, Vet_approved Phase 4 54-05-7 2719
28
Azathioprine Approved Phase 4 446-86-6 2265
29
Atorvastatin Approved Phase 4 134523-00-5 60823
30
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
31
Tranexamic Acid Approved Phase 4 1197-18-8 5526
32
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
33
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
34
Tolvaptan Approved Phase 4 150683-30-0 216237
35
Ethanol Approved Phase 4 64-17-5 702
36
Acetylcysteine Approved, Investigational Phase 4 616-91-1 12035
37
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
38
Lorazepam Approved Phase 4 846-49-1 3958
39
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
40
Isoleucine Approved, Investigational, Nutraceutical Phase 4 443-79-8, 73-32-5 6306
41
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
42 Hypoglycemic Agents Phase 4
43 arginine Phase 4
44 Adjuvants, Anesthesia Phase 4
45 Anesthetics, General Phase 4
46 Anesthetics, Intravenous Phase 4
47 Amoxicillin-Potassium Clavulanate Combination Phase 4
48 Antitubercular Agents Phase 4
49 Antiparasitic Agents Phase 4
50 Acidophilus Phase 4

Interventional clinical trials:

(show top 50) (show all 304)
# Name Status NCT ID Phase Drugs
1 Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy: A Randomized Open Controlled Study Unknown status NCT03077217 Phase 4 Rifaximin
2 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis: An Open Label, Randomized Controlled Trial of Lactulose, Probiotics and No-therapy Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
3 Primary Prophylaxis of Hepatic Encephalopathy in Patients With Cirrhosis: an Open Labeled Randomized Controlled Trial of Lactulose Versus no Lactulose Unknown status NCT01175538 Phase 4 Lactulose;Lactulose
4 Metformin Experience on Minimal Hepatic Encephalopathy in Patients With Liver Cirrhosis Unknown status NCT02470546 Phase 4 Metformin;Placebo
5 Efficacy of Combined Oral L-Ornithine-L-Aspartate and Oral Lactulose in Patients With Hepatic Encephalopathy Unknown status NCT00740142 Phase 4 L-ornithine-L-aspartate and lactulose;placebo and lactulose
6 Therapeutic Efficacy of Oral L-Ornithine-L-Aspartate on Liver Cirrhosis and Minimal Encephalopathy: a Single Center Placebo Control Double Blind Study Unknown status NCT00896831 Phase 4 L-ornithine-L-aspartate;placebo
7 A Randomized Comparison of Rifaximin Versus Lactulose in Hospitalized Cirrhotic Patients With Progressive Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
8 Randomized Controlled Trial Comparing Effects of Sedation for Upper Gastrointestinal Endoscopy With Propofol Versus Midazolam on Psychometric Tests and Critical Flicker Frequency in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
9 Magnesium Deficiency in Cirrhotic Patients Unknown status NCT01894867 Phase 4
10 Efficacy and Safety Study of Tolvaptan for Liver Cirrhotic Patients With Hyponatremia and Ascites: A Multi-center, Randomized, Double-blind, Placebo-controlled 4-weeks Clinical Trial Unknown status NCT01716611 Phase 4 Tolvaptan;placebo
11 Bacterial Infections Associated With Healthcare (Healthcare-Associated) in Hospitalized Cirrhotic Patients: Randomized Study of Use of Traditional Empirical Antibiotic Therapy and Second-line Targeted at Multi-resistant Bacteria Unknown status NCT01820026 Phase 4 Imipenem;Vancomycin;azithromycin;Cefotaxime;Amoxicillin
12 Effect of Albumine Infusion in the Prevention of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt Completed NCT01559519 Phase 4 Albumin
13 High-fiber High-fiber Diet and Branched Chain Aminoacids. Impact on Nutritional Status and Complications in Patients With Liver Cirrhosis Completed NCT02023229 Phase 4
14 A Multicenter, Randomized, Open-Label, Active-Controlled, Trial To Evaluate The Safety And Efficacy Of Rifaximin 550 Mg With And Without Lactulose In Subjects With A History Of Recurrent Overt Hepatic Encephalopathy Completed NCT01842581 Phase 4 Rifaximin;Rifaximin and Lactulose
15 Effect of the Proteins of the Diet in Patients With Cirrhosis and a Prior Episode of Hepatic Encephalopathy. A Randomized Study Completed NCT00955500 Phase 4
16 Effect of Lactulose on Minimal Hepatic Encephalopathy and Health-Related Quality of Life Completed NCT00375375 Phase 4 Lactulose
17 Effects of the Administration of Albumin in Patients With Cirrhosis and Acute Hepatic Encephalopathy. Completed NCT00886925 Phase 4 Albumin;Sodium chloride 0.9%
18 The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy. Completed NCT01041755 Phase 4 L-ornithine-L-aspartate;Lactose
19 Comparison of Three Different Schemes:Lactulose, L-ornithine L-aspartate, or Rifaximin, Versus Placebo, as Primary Prophylaxis of the Development of Hepatic Encephalopathy After Acute Variceal Bleeding in Cirrhotic Patients Completed NCT02158182 Phase 4 Lactulose;L-ornithine L-aspartate;Rifaximin;Placebo
20 LOLA in Hepatic Encephalopathy Brain Muscle Axis During Treatment of Hepatic Encephalopathy With L-ornithine L-aspartate A Phase iv Randomised Double Blind Placebo- Controlled Trial Completed NCT01847651 Phase 4 LOLA or placebo
21 A Placebo Controlled Single Centre Double Blind Randomised Trial to Investigate the Efficacy of Rifaximin Versus Placebo in Improving Systemic Inflammation and Neutrophil Malfunction in Patients With Cirrhosis and Chronic Hepatic Encephalopathy Completed NCT02019784 Phase 4 Rifaximin-α;Placebo Oral Tablet
22 Multicenter, Randomized, Double-blind, Placebo-controlled Study on the Effectiveness of Treatment With Beta-blockers to Prevent Decompensation of Cirrhosis With Portal Hypertension Completed NCT01059396 Phase 4 propranolol;carvedilol;placebo
23 A Clinical Trial of the Vessel Sealing System (LigaSure) in Azygoportal Disconnection and Splenectomy in Patients With Portal Hypertension Completed NCT00965744 Phase 4
24 Safety and Efficacy of Steroids in the Management of Fulminant Hepatic Failure Due to Hepatitis A Virus in the Pediatric Age Group Completed NCT02375867 Phase 4 prednisolone;methylprednisolone
25 Efficacy of Intravenous 'L-ornithine L-aspartate' in Reversal of Overt Acute Hepatic Encephalopathy in Patients With Liver Cirrhosis: a Prospective, Randomized, Double-blind, Placebo Controlled Trial Completed NCT01722578 Phase 4 L-ornithine L-aspartate;Placebo
26 A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B Completed NCT00380614 Phase 4 Lamivudine
27 Midodrine and Albumin for Cirrhotic Patients in the Waiting List for Liver Transplantation Completed NCT00839358 Phase 4 albumin;Midodrine;Placebo
28 Pharmacokinetics of Buprenorphine and Naloxone in Subjects With Mild to Severe Hepatic Impairment (Child-Pugh Classes, A, B, and C), in HCV-Seropositive Subjects, and in Healthy Volunteers Completed NCT01846455 Phase 4 2.0mg Buprenorphine/0.5mg Naloxone;Promethazine
29 Intestinal Decontamination With Rifaximin. Effects on the Inflammatory and Circulatory State in Patients With Cirrhosis and Ascites - A Randomised Controlled Clinical Study Completed NCT01769040 Phase 4 Rifaximin;placebo
30 Ramelteon for Treatment of Insomnia in Cirrhosis Completed NCT03091738 Phase 4 Ramelteon Pill
31 Study of the Effect of VSL#3 (Original De Simone Formulation) on Cognitive Function, Risk of Falls and Quality of Life in Patients With Cirrhosis Completed NCT01686698 Phase 4
32 Possible Role of Chloroquine in Conjunction to Prednisone to Induce a Complete Remission in the Treatment of Autoimmune Hepatitis: a Randomized Trial Completed NCT02463331 Phase 4 Chloroquine diphosphate;prednisone;azathioprine
33 DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL WITH CHLOROQUINE VERSUS PLACEBO FOR MAINTENANCE OF REMISSION OF AUTOIMMUNE HEPATITIS Completed NCT01980745 Phase 4 Chloroquine diphosphate 250mg;Placebo
34 The Use of Human Albumin for the Treatment of Ascites in Patients With Hepatic Cirrhosis: a Multicenter, Open-label Randomized Clinical Trial Completed NCT01288794 Phase 4 Diuretics plus human albumin;Diuretics (standard medical treatment)
35 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy Recruiting NCT01846663 Phase 4 Placebo;Rifaximin
36 Albumin Infusion Effects in Mortality in Patients With Cirrhosis and Hepatic Encephalopathy Recruiting NCT02401490 Phase 4 Human albumin;Placebo
37 Randomized Trial Comparing The Efficacy of PEG (Polyethylene Glycol) Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Recruiting NCT03100513 Phase 4 Lactulose;Polyethylene Glycol
38 Therapeutic Efficacy of Oral PEG3350 Plus Lactulose Versus Lactulose Alone in Patients of Acute on Chronic Liver Failure With Overt Hepatic Encephalopathy: A Single Blind Prospective Randomized Controlled Study Recruiting NCT03987893 Phase 4 PEG-3350 with Electolytes;Lactulose
39 Statin for Preventing Hepatocellular Carcinoma Recurrence After Curative Treatment: a Double-blind Randomized Placebo-controlled Trial Recruiting NCT03024684 Phase 4 Atorvastatin;Placebo Oral Tablet
40 Efficacy and Safety of Early Administration of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding: a Multicenter, Randomized, Double Blind, Placebo-controlled Trial (Modified by amendment1) Recruiting NCT03023189 Phase 4 Tranexamic acid;Placebo
41 Functional MRI-based Assessment of Terlipressin vs. Octreotide on Renal Function in Cirrhotic Patients With Acute Variceal Bleeding (CHESS1903): A Multicenter, Single-blind, Randomised Controlled Trial Recruiting NCT04028323 Phase 4 Terlipressin;Octreotide
42 Treatment of Sarcopenia Improves the Muscle Mass and Muscle Strength of Patients With Liver Cirrhosis- Child C: A Randomized Double Blind Control Trial Recruiting NCT03633279 Phase 4 Branched chain amino acid;Placebo
43 Quality of Life and Nutritional Improvements in Cirrhotic Patients Following Hepatic Encephalopathy Using Rifaximin. Terminated NCT01842113 Phase 4 Rifaximin;Lactulose;Lactulose Placebo;Rifaximin Placebo
44 Effects of Intrathoracic Pressure Regulation Therapy in Patients With Elevated Intracranial Pressure Due to Brain Injury or Intracranial Pathology Terminated NCT01824589 Phase 4
45 A Multi-Center Trial to Study Acute Liver Failure: N-Acetylcysteine (NAC) Open Label Use Study Terminated NCT00896025 Phase 4 N-acetylcysteine
46 Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia Terminated NCT01890694 Phase 4 Tolvaptan;Placebo
47 A Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Dexmedetomidine (Precedex®), With Lorazepam Rescue, for the Management of Severe Alcohol Withdrawal Syndrome (AWS) and Alcohol Withdrawal Delirium (AWD) Terminated NCT01362205 Phase 4 Dexmedetomidine;Placebos
48 Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease Withdrawn NCT01654939 Phase 4 Rifaximin
49 RICE Trial: Rifaximin In Chronic Hepatic Encephalopathy - A Randomized, Controlled Trial Unknown status NCT00364689 Phase 3 Rifaximin alone, Rifaximin combined with Lactulose
50 A Randomized, Double-blind, Controlled Trial Comparing Nitazoxanide Plus Lactulose With Lactulose Alone Treatment of Overt Hepatic Encephalopathy Unknown status NCT02464124 Phase 2, Phase 3 Nitazoxanide;Lactulose

Search NIH Clinical Center for Hepatic Coma

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Kanamycin Sulfate
Lactulose
NEOMYCIN SO4 PWDR
Paromomycin

Cochrane evidence based reviews: hepatic encephalopathy

Genetic Tests for Hepatic Coma

Anatomical Context for Hepatic Coma

MalaCards organs/tissues related to Hepatic Coma:

41
Liver, Brain, Testes, Cortex, Colon, Kidney, Cerebellum

Publications for Hepatic Coma

Articles related to Hepatic Coma:

(show top 50) (show all 8913)
# Title Authors PMID Year
1
Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma. 9 38
16563564 2006
2
The "peripheral-type" benzodiazepine (omega 3) receptor in hyperammonemic disorders. 9 38
12020611 2002
3
Influence of acute and chronic alcohol intake on the clinical course and outcome in acetaminophen overdose. 9 38
11929388 2002
4
Acute liver failure. 9 38
11132456 1999
5
The effect of flumazenil on subclinical psychometric or neurophysiological alterations in cirrhotic patients: a double-blind placebo-controlled study. 9 38
9347201 1997
6
[Severe Amanita phalloides poisoning in a 7-year-old girl]. 9 38
8348662 1993
7
"Peripheral-type" (mitochondrial) benzodiazepine receptors in hepatic encephalopathy. 9 38
7748297 1993
8
Significance of serum human hepatocyte growth factor levels in patients with hepatic failure. 9 38
1530786 1992
9
Increased densities of peripheral-type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. 9 38
2161396 1990
10
Calcium-dependent kinases in the brain have site-specific associations with locomotion and rearing impairments in rats with bile duct ligation. 38
31173796 2019
11
Ammonium induced dysfunction of 5-HT2B receptor in astrocytes. 38
31145970 2019
12
Alarming trends in hepatic encephalopathy in the USA. 38
31385872 2019
13
Longitudinal neurometabolic changes in the hippocampus of a rat model of chronic hepatic encephalopathy. 38
31173812 2019
14
Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients. 38
31107304 2019
15
Hepatic encephalopathy resulting in mania, a possible role of bilirubin and glutamate? 38
31400251 2019
16
Critical flickering frequency test: a diagnostic tool for minimal hepatic encephalopathy. 38
31274595 2019
17
Clinical Predictors for Poor Quality of Life in Patients With Covert Hepatic Encephalopathy. 38
30439761 2019
18
A model to predict early hepatic encephalopathy in patients undergoing transjugular intrahepatic portosystemic shunt. 38
31418414 2019
19
Supplementation with Synbiotics and/or Branched Chain Amino Acids in Hepatic Encephalopathy: A Pilot Randomised Placebo-Controlled Clinical Study. 38
31390762 2019
20
Impaired brain glucose metabolism in cirrhosis without overt hepatic encephalopathy: a retrospective 18F-FDG PET/CT study. 38
31261240 2019
21
Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. 38
30289992 2019
22
Associated vitamin D deficiency is a risk factor for the complication of HCV-related liver cirrhosis including hepatic encephalopathy and spontaneous bacterial peritonitis. 38
30706253 2019
23
Letter to the Editor: Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. 38
30959562 2019
24
Problematic Cannabis Use and Risk of Complications in Patients with Chronic Hepatitis C. 38
31431849 2019
25
Donor Age Predicts Calcineurin Inhibitor Induced Neurotoxicity After Liver Transplantation. 38
30985573 2019
26
Flare of Autoimmune Hepatitis Causing Acute on Chronic Liver Failure: Diagnosis and Response to Corticosteroid Therapy. 38
30113706 2019
27
Domoic acid suppresses hyperexcitation in the network due to activation of kainate receptors of GABAergic neurons. 38
31220431 2019
28
Rifaximin reduces the incidence of spontaneous bacterial peritonitis, variceal bleeding and all-cause admissions in patients on the liver transplant waiting list. 38
31169941 2019
29
Percutaneous transvenous shunt occlusion for portosystemic encephalopathy due to lenvatinib administration to a patient with hepatocellular carcinoma and portosystemic shunt. 38
30706429 2019
30
Biomarkers for oralization during long-term proton pump inhibitor therapy predict survival in cirrhosis. 38
31427714 2019
31
Cognitive impairments in HCV infection: From pathogenesis to neuroimaging. 38
31405320 2019
32
Validation of Risk Score in Predicting Early Readmissions in Decompensated Cirrhotic Patients: A Model Based on the Administrative Database. 38
30218583 2019
33
Mechanism of Fibrosis Induced by Echinococcus spp. 38
31409055 2019
34
Machine Learning-based Development and Validation of a Scoring System for Screening High-Risk Esophageal Varices. 38
30708109 2019
35
[Esophageal variceal bleeding: management and tips on transjugular intrahepatic portosystemic shunt]. 38
30963209 2019
36
Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. 38
31153882 2019
37
Critically Ill Patients with End-Stage Liver Disease. 38
31262418 2019
38
Cerebral water content mapping in cirrhosis patients with and without manifest HE. 38
31089866 2019
39
Exhaled breath analysis in hepatology: State-of-the-art and perspectives. 38
31435162 2019
40
Zinc supplementation in patients with cirrhosis and hepatic encephalopathy: a systematic review and meta-analysis. 38
31279342 2019
41
Dopamine Burden Triggers Cholesterol Overload Following Disruption of Synaptogenesis in Minimal Hepatic Encephalopathy. 38
31078686 2019
42
A hydrodynamic hypothesis for the pathogenesis of glymphatic system impairment in hepatic encephalopathy. 38
31060841 2019
43
Association between sarcopenia and hepatic encephalopathy: A systematic review and meta-analysis. 38
31422030 2019
44
Tadalafil restores long-term memory and synaptic plasticity in mice with hepatic encephalopathy. 38
31323263 2019
45
Hepatic Encephalopathy in Children With Acute Liver Failure: Utility of Serum Neuromarkers. 38
31058776 2019
46
Short-Term Proton Pump Inhibitor Use and Hepatic Encephalopathy Risk in Patients with Decompensated Cirrhosis. 38
31349746 2019
47
Teaching Video NeuroImages: Hepatic myelopathy: An unusual neurologic complication of hepatic encephalopathy. 38
31308174 2019
48
Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy. 38
31347756 2019
49
Hippocampal atrophy and functional connectivity disruption in cirrhotic patients with minimal hepatic encephalopathy. 38
31363985 2019
50
Ameliorative effect of Magnesium Isoglycyrrhizinate on hepatic encephalopathy by Epirubicin. 38
31351363 2019

Variations for Hepatic Coma

Expression for Hepatic Coma

Search GEO for disease gene expression data for Hepatic Coma.

Pathways for Hepatic Coma

Pathways related to Hepatic Coma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.02 DBI ACACA
2 10.6 F2 ALB
3
Show member pathways
9.88 TSPO DBI

GO Terms for Hepatic Coma

Cellular components related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.35 TSPO GPT F2 DBI ALB
2 endoplasmic reticulum lumen GO:0005788 8.8 F2 DBI ALB

Biological processes related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of reactive oxygen species metabolic process GO:2000379 8.62 TSPO F2

Molecular functions related to Hepatic Coma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 pyridoxal phosphate binding GO:0030170 8.62 GPT ALB

Sources for Hepatic Coma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....